Publicacións en colaboración con investigadores/as de Universitat de Barcelona (70)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

  3. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

    Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

  4. Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study

    Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8

  5. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

  6. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  7. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 25, Núm. 11, pp. 1453-1464

  8. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients

    Scientific reports, Vol. 14, Núm. 1, pp. 3188

  9. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

    Clinical and Translational Oncology

  10. Unveiling the Significance of HLA and KIR Diversity in Underrepresented Populations

    Biomedicines, Vol. 12, Núm. 6

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study

    Oncologist, Vol. 28, Núm. 11, pp. 986-995

  3. Cancer-associated fibroblasts actively compress cancer cells and modulate mechanotransduction

    Nature communications, Vol. 14, Núm. 1, pp. 6966

  4. Coping strategies as mediators of uncertainty and psychological distress in patients with advanced cancer

    Psycho-Oncology, Vol. 32, Núm. 11, pp. 1694-1701

  5. MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles

    iScience, Vol. 26, Núm. 3

  6. Mental Adjustment, Functional Status, and Depression in Advanced Cancer Patients

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 4

  7. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database

    eClinicalMedicine, Vol. 58

  8. Psychological factors and prognostic communication preferences in advanced cancer: multicentre study

    BMJ Supportive and Palliative Care, Vol. 13, Núm. e3, pp. E1342-E1350

  9. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

    Lung Cancer, Vol. 178, pp. 116-122

  10. The Relationship between Therapeutic Alliance and Quality of Care in Patients with Advanced Cancer in Spain

    Current Oncology, Vol. 30, Núm. 4, pp. 3580-3589